Rivaroxaban Impurity 140 | CAS 2138262-09-4 - Request Quote
Rivaroxaban Impurity 140
| SZ CAT No: | SZ-R017214 |
| CAS No | 2138262-09-4 |
| Mol.F. | C10H9N3O6 |
| Mol.Wt. | 267.2 |
| Inv. Status | In Stock |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Rivaroxaban Impurity 140 is chemically 4-(3,5-Dinitrophenyl)morpholin-3-one. Rivaroxaban Impurity 140 is supplied with detailed characterization data compliant with regulatory guideline. Rivaroxaban Impurity 140 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Rivaroxaban.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 2138262-09-4
Purchase 2138262-09-4
Order 2138262-09-4
Enquire 2138262-09-4
price of 2138262-09-4
2138262-09-4 Supplier
2138262-09-4 Manufacturer
2138262-09-4 Exporter
buy high quality Rivaroxaban Impurity 140
Purchase Rivaroxaban Impurity 140
Rivaroxaban Impurity 140 suppliers
Rivaroxaban Impurity 140 manufacturers
Rivaroxaban Impurity 140 price
Order Rivaroxaban Impurity 140
Enquire Rivaroxaban Impurity 140
Rivaroxaban Impurity 140 cost
Rivaroxaban Impurity 140 Supplier
Rivaroxaban Impurity 140 Distributor
Rivaroxaban Impurity 140 for Method Validation
Rivaroxaban Reference Standard
Rivaroxaban Impurity 140 for ANDA Filing
Rivaroxaban Impurity 140 for Forced Degradation Studies
Rivaroxaban Impurity 140 Identification Standards
Rivaroxaban Impurity 140 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.